QuickLinks -- Click here to rapidly navigate through this document
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 3, 2003
CUBIST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) | | 0-21379
(Commission
File Number) | | 22-3192085
(IRS Employer
Identification No.) |
65 Hayden Avenue, Lexington, Massachusetts 02421
(Address of Principal Executive Offices) (Zip Code) |
Registrant's telephone number, including area code:(781) 860-8660
On October 3, 2003, the Registrant issued a joint press release announcing an international commercialization agreement with Chiron Corporation for the development and commercialization of Cubicin (daptomycin for injection) in Western and Eastern Europe, Australia, New Zealand, India and certain Central American, South American and Middle Eastern countries. The press release has been filed as an exhibit to this Report on Form 8-K, attached hereto as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CUBIST PHARMACEUTICALS, INC. |
|
|
|
|
|
| | | By: | /s/ CHRISTOPHER D.T. GUIFFRE
Christopher D.T. Guiffre
Vice President, General Counsel and Secretary |
Dated: October 3, 2003
QuickLinks
SIGNATURES
